Positive study results confirm the unique capability of using PreciseInhale in a clinical setting
(Stockholm, 20 December, 2021) Results from a recently completed clinical study demonstrate that PreciseInhale® has reached its clinical objectives. CEO Manoush Masarrat: “This is one of the most important milestones to date in our company’s history. It unlocks new markets with an estimated market potential of minimum 5 billion SEK, plus it gives the entire inhalation research sector new capabilities including a new benchmark for aerosol precision and dosing.”Topline data confirm that ISAB’s flagship aerosol generating system PreciseInhale has reached its clinical objectives, with no